Foritinib succinate vs Lorlatinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ALK / ROS1 · full Non-Small Cell Lung Cancer pipeline

Foritinib succinate

Developed by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT06569420 · Phase 3 · active, not recruiting

This was a randomized, actively-controlled (crizotinib) Phase 3 trial with 275 patients and a hard clinical primary endpoint (independently reviewed progression-free survival), and outside reporting indicates the trial clearly met this endpoint with a large PFS benefit favoring foritinib. However, the study was open-label with no blinding of patients or investigators, which limits confidence in outcome assessments that could be influenced by knowledge of treatment assignment, so it falls short of the highest evidence tier despite the favorable, statistically robust result.

Reported efficacy

Progression-free survival (PFS) by IRC (up to 36 months); Overall survival (OS) (up to 60 months); Progression-free survival (PFS) by INV (up to 36 months); Objective Response Rate (ORR) by IRC and INV (up to 36 months); Duration of response (DOR) by IRC and INV (up to 36 months); to evaluate the C-ORR in patient with CNS metastases. (up to 36 months); to assess the C-TTR in patient who have as CNS objective response (up to 36 months); to assess the C-DOR in patient who have as CNS objective response. (up to 36 months); to assess the C-TTP in patient who have as CNS objective response. (up to 36 months); The time to CNS progression in ITT by IRC. (up to 36 months); Incidence of adverse events. (up to 36 months); Health-Related Quality of Life (HRQoL) by EORTC Quality of Life Questionnaire C30 Score (up to 36 months); Health-Related Quality of Life (HRQoL) by EORTC Quality of Life Questionnaire LC13 Score (up to 36 months): Phase III SAF-189s vs crizotinib trial (NCT06569420), primary endpoint IRC-assessed PFS: median not reached (SAF-189s/foritinib) vs 13.93 months (crizotinib); HR 0.23 (95% CI 0.14-0.38) (met)

Result source: NCT06569420

Lorlatinib

Marketed by Pfizer

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT03052608 · Phase 3 · active, not recruiting

People were randomized to lorlatinib or the active comparator crizotinib and progression-free survival was read by blinded independent review, with a clear significant result in 296 people. The trial was open-label, so participants and investigators knew the treatment.

Next expected readout: December 2026 · NCT05059522 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointForitinib succinateLorlatinib
PFS, median—Trial running · NCT0656942016.6bn 30NCT01970865
11 other results
OS, median—Trial running · NCT0656942052.5bn 27NCT01970865
4 other results
ORR—Trial running · NCT0656942075.8% vs 57.8%vs Crizotinibn 149NCT03052608
4 other results
Duration of response, median—Trial running · NCT0656942020.9bn 26NCT04362072
4 other results

PFS, median

Foritinib succinate
—Trial running · NCT06569420
Lorlatinib
16.6bn 30NCT01970865
11 other results

OS, median

Foritinib succinate
—Trial running · NCT06569420
Lorlatinib
52.5bn 27NCT01970865
4 other results

ORR

Foritinib succinate
—Trial running · NCT06569420
Lorlatinib
75.8% vs 57.8%vs Crizotinibn 149NCT03052608
4 other results

Duration of response, median

Foritinib succinate
—Trial running · NCT06569420
Lorlatinib
20.9bn 26NCT04362072
4 other results
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Foritinib succinate
Phase III SAF-189s vs crizotinib trial (NCT06569420), primary endpoint IRC-assessed PFS: median not reached (SAF-189s/foritinib) vs 13.93 months (crizotinib); HR 0.23 (95% CI 0.14-0.38) NCT06569420 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Foritinib succinate: 0 of 4 rows · Lorlatinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLorlatinib
Dropout rate
82.6%a
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 22 more results
82.4%100 mg QD
NCT01970865 · Phase 1/2
100%200 mg QD
NCT01970865 · Phase 1/2
100%150 mg QD
NCT01970865 · Phase 1/2
50%100 mg BID
NCT01970865 · Phase 1/2
66.7%75 mg BID
NCT01970865 · Phase 1/2
83.3%75 mg QD
NCT01970865 · Phase 1/2
100%50 mg QD
NCT01970865 · Phase 1/2
100%35 mg BID
NCT01970865 · Phase 1/2
100%25 mg QD
NCT01970865 · Phase 1/2
100%10 mg QD
NCT01970865 · Phase 1/2
40%EXP-1 (Phase 2)
NCT01970865 · Phase 1/2
74.1%EXP-2 (Phase 2)
NCT01970865 · Phase 1/2
70%EXP-3 (Phase 2)
NCT01970865 · Phase 1/2
87.7%EXP-4 (Phase 2)
NCT01970865 · Phase 1/2
93.5%EXP-5 (Phase 2)
NCT01970865 · Phase 1/2
85.1%EXP-6 (Phase 2)
NCT01970865 · Phase 1/2
33.3%Japan Lead-In Cohort (LIC)
NCT01970865 · Phase 1/2
—100mg
NCT04362072 · Phase 4 · registry result, not featured evidence
n/a: no completion milestoneLorlatinib
NCT04362072 · Phase 4 · registry result, not featured evidence
45%100 mg QD
NCT04541706 · Phase 4 · registry result, not featured evidence
n/a: no completion milestoneCohort 1
NCT03909971 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort 2
NCT03909971 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
6.7%a
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 22 more results
—100 mg QD
NCT01970865 · Phase 1/2
—200 mg QD
NCT01970865 · Phase 1/2
—150 mg QD
NCT01970865 · Phase 1/2
—100 mg BID
NCT01970865 · Phase 1/2
—75 mg BID
NCT01970865 · Phase 1/2
—75 mg QD
NCT01970865 · Phase 1/2
—50 mg QD
NCT01970865 · Phase 1/2
—35 mg BID
NCT01970865 · Phase 1/2
—25 mg QD
NCT01970865 · Phase 1/2
—10 mg QD
NCT01970865 · Phase 1/2
—EXP-1 (Phase 2)
NCT01970865 · Phase 1/2
—EXP-2 (Phase 2)
NCT01970865 · Phase 1/2
—EXP-3 (Phase 2)
NCT01970865 · Phase 1/2
—EXP-4 (Phase 2)
NCT01970865 · Phase 1/2
—EXP-5 (Phase 2)
NCT01970865 · Phase 1/2
—EXP-6 (Phase 2)
NCT01970865 · Phase 1/2
—Japan Lead-In Cohort (LIC)
NCT01970865 · Phase 1/2
—100mg
NCT04362072 · Phase 4 · registry result, not featured evidence
1.4%Lorlatinib
NCT04362072 · Phase 4 · registry result, not featured evidence
1%100 mg QD
NCT04541706 · Phase 4 · registry result, not featured evidence
1.5%Cohort 1
NCT03909971 · Phase 2 · registry result, not featured evidence
4.8%Cohort 2
NCT03909971 · Phase 2 · registry result, not featured evidence
Serious AEs
34.2%a
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 22 more results
58.8%100 mg QD
NCT01970865 · Phase 1/2
66.7%200 mg QD
NCT01970865 · Phase 1/2
100%150 mg QD
NCT01970865 · Phase 1/2
50%100 mg BID
NCT01970865 · Phase 1/2
66.7%75 mg BID
NCT01970865 · Phase 1/2
50%75 mg QD
NCT01970865 · Phase 1/2
33.3%50 mg QD
NCT01970865 · Phase 1/2
66.7%35 mg BID
NCT01970865 · Phase 1/2
66.7%25 mg QD
NCT01970865 · Phase 1/2
100%10 mg QD
NCT01970865 · Phase 1/2
50%EXP-1 (Phase 2)
NCT01970865 · Phase 1/2
40.7%EXP-2 (Phase 2)
NCT01970865 · Phase 1/2
56.7%EXP-3 (Phase 2)
NCT01970865 · Phase 1/2
47.7%EXP-4 (Phase 2)
NCT01970865 · Phase 1/2
50%EXP-5 (Phase 2)
NCT01970865 · Phase 1/2
44.7%EXP-6 (Phase 2)
NCT01970865 · Phase 1/2
33.3%Japan Lead-In Cohort (LIC)
NCT01970865 · Phase 1/2
32.4%100mg
NCT04362072 · Phase 4 · registry result, not featured evidence
—Lorlatinib
NCT04362072 · Phase 4 · registry result, not featured evidence
22%100 mg QD
NCT04541706 · Phase 4 · registry result, not featured evidence
34.3%Cohort 1
NCT03909971 · Phase 2 · registry result, not featured evidence
38.1%Cohort 2
NCT03909971 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
hypertriglyceridaemia 52.3%
oedema peripheral 43.6%
blood cholesterol increased 39.6%
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 21 more results
100 mg QD
hypercholesterolaemia 70.6%
oedema peripheral 58.8%
anaemia 41.2%
NCT01970865 · Phase 1/2
200 mg QD
hypercholesterolaemia 100%
affect lability 66.7%
aspartate aminotransferase increased 66.7%
NCT01970865 · Phase 1/2
150 mg QD
anaemia 100%
hypomagnesaemia 100%
oedema peripheral 100%
NCT01970865 · Phase 1/2
100 mg BID
diarrhoea 75%
fatigue 75%
nausea 75%
NCT01970865 · Phase 1/2
75 mg BID
anaemia 66.7%
neuropathy peripheral 66.7%
oedema peripheral 66.7%
NCT01970865 · Phase 1/2
75 mg QD
hypercholesterolaemia 58.3%
blood cholesterol increased 50%
fatigue 41.7%
NCT01970865 · Phase 1/2
50 mg QD
asthenia 66.7%
abdominal pain upper 33.3%
aspartate aminotransferase increased 33.3%
NCT01970865 · Phase 1/2
35 mg BID
dyspnoea 100%
paraesthesia 66.7%
abdominal pain upper 33.3%
NCT01970865 · Phase 1/2
25 mg QD
cough 66.7%
hypercholesterolaemia 66.7%
hypophosphataemia 66.7%
NCT01970865 · Phase 1/2
10 mg QD
oedema peripheral 100%
amylase increased 66.7%
aphasia 66.7%
NCT01970865 · Phase 1/2
hypertriglyceridaemia 76.7%
hypercholesterolaemia 53.3%
oedema peripheral 43.3%
NCT01970865 · Phase 1/2
hypertriglyceridaemia 59.3%
oedema peripheral 55.6%
hypercholesterolaemia 51.9%
NCT01970865 · Phase 1/2
hypertriglyceridaemia 61.7%
hypercholesterolaemia 55%
oedema peripheral 55%
NCT01970865 · Phase 1/2
hypertriglyceridaemia 69.2%
hypercholesterolaemia 58.5%
oedema peripheral 38.5%
NCT01970865 · Phase 1/2
hypertriglyceridaemia 69.6%
hypercholesterolaemia 58.7%
blood cholesterol increased 34.8%
NCT01970865 · Phase 1/2
alanine aminotransferase increased 100%
hypercholesterolaemia 53.2%
hypertriglyceridaemia 53.2%
NCT01970865 · Phase 1/2
blood cholesterol increased 100%
hypertriglyceridaemia 100%
alanine aminotransferase increased 66.7%
NCT01970865 · Phase 1/2
100mg
hypertriglyceridaemia 38%
oedema peripheral 36.6%
hypercholesterolaemia 33.8%
NCT04362072 · Phase 4 · registry result, not featured evidence
100 mg QD
hypertriglyceridaemia 58%
hypercholesterolaemia 57%
weight increased 39%
NCT04541706 · Phase 4 · registry result, not featured evidence
hypertriglyceridaemia 89.6%
weight increased 73.1%
hypercholesterolaemia 61.2%
NCT03909971 · Phase 2 · registry result, not featured evidence
hypertriglyceridaemia 76.2%
hypercholesterolaemia 69%
alanine aminotransferase increased 45.2%
NCT03909971 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 22 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lorlatinib

PFS NA vs 9.3 Crizotinib months
time to event · months
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
NA vs 9.1 Crizotinib months
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival NA vs NA Crizotinib months
time to event · months
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 75.8% (n=149) vs 57.8% (n=147) Crizotinib
responder rate · % of participants
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
80.5% (n=149) vs 61.9% (n=147) Crizotinib
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Duration of Response NA vs 11 Crizotinib months
time to event · months
NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 90% (n=30)
responder rate · % of participants
No placebo or comparator arm
Objective response
NCT01970865 · Phase 1/2
show 11 more results
74.1% (n=27)
Objective response
NCT01970865 · Phase 1/2
50.8% (n=60)
Objective response
NCT01970865 · Phase 1/2
41.5% (n=65)
Objective response
NCT01970865 · Phase 1/2
34.8% (n=46)
Objective response
NCT01970865 · Phase 1/2
36.2% (n=47)
Objective response
NCT01970865 · Phase 1/2
90% (n=30)
Objective response
NCT01970865 · Phase 1/2
77.8% (n=27)
Objective response
NCT01970865 · Phase 1/2
56.7% (n=60)
Objective response
NCT01970865 · Phase 1/2
40% (n=65)
Objective response
NCT01970865 · Phase 1/2
37% (n=46)
Objective response
NCT01970865 · Phase 1/2
38.3% (n=47)
Objective response
NCT01970865 · Phase 1/2
Intracranial ORR 75% (n=30)
responder rate · % of participants
No placebo or comparator arm
Intracranial objective response
NCT01970865 · Phase 1/2
show 11 more results
58.8% (n=27)
Intracranial objective response
NCT01970865 · Phase 1/2
62.5% (n=60)
Intracranial objective response
NCT01970865 · Phase 1/2
55.6% (n=65)
Intracranial objective response
NCT01970865 · Phase 1/2
39.5% (n=46)
Intracranial objective response
NCT01970865 · Phase 1/2
56% (n=47)
Intracranial objective response
NCT01970865 · Phase 1/2
75% (n=30)
Intracranial objective response
NCT01970865 · Phase 1/2
58.8% (n=27)
Intracranial objective response
NCT01970865 · Phase 1/2
66.7% (n=60)
Intracranial objective response
NCT01970865 · Phase 1/2
53.3% (n=65)
Intracranial objective response
NCT01970865 · Phase 1/2
43.2% (n=46)
Intracranial objective response
NCT01970865 · Phase 1/2
56% (n=47)
Intracranial objective response
NCT01970865 · Phase 1/2
Time to Response 1.4 months
time to event · months
No placebo or comparator arm
TTR
NCT01970865 · Phase 1/2
show 5 more results
1.4 months
TTR
NCT01970865 · Phase 1/2
1.4 months
TTR
NCT01970865 · Phase 1/2
2.6 months
TTR
NCT01970865 · Phase 1/2
1.4 months
TTR
NCT01970865 · Phase 1/2
1.4 months
TTR
NCT01970865 · Phase 1/2
Time to Intra-Cranial Response 2.1 months
time to event · months
No placebo or comparator arm
Intracranial TTR
NCT01970865 · Phase 1/2
show 5 more results
1.4 months
Intracranial TTR
NCT01970865 · Phase 1/2
1.4 months
Intracranial TTR
NCT01970865 · Phase 1/2
1.7 months
Intracranial TTR
NCT01970865 · Phase 1/2
1.4 months
Intracranial TTR
NCT01970865 · Phase 1/2
1.4 months
Intracranial TTR
NCT01970865 · Phase 1/2
Duration of Response 17.16 months
time to event · months
No placebo or comparator arm
DOR
NCT01970865 · Phase 1/2
show 5 more results
16.56 months
DOR
NCT01970865 · Phase 1/2
11.1 months
DOR
NCT01970865 · Phase 1/2
15.08 months
DOR
NCT01970865 · Phase 1/2
7.03 months
DOR
NCT01970865 · Phase 1/2
19.61 months
DOR
NCT01970865 · Phase 1/2
Intracranial Duration of Response NA months
time to event · months
No placebo or comparator arm
Intra-cranial DOR
NCT01970865 · Phase 1/2
show 5 more results
NA months
Intra-cranial DOR
NCT01970865 · Phase 1/2
37.12 months
Intra-cranial DOR
NCT01970865 · Phase 1/2
14.52 months
Intra-cranial DOR
NCT01970865 · Phase 1/2
10.32 months
Intra-cranial DOR
NCT01970865 · Phase 1/2
17.62 months
Intra-cranial DOR
NCT01970865 · Phase 1/2
Disease Control 93.3% (n=30) @ 12wk
responder rate · % of participants
No placebo or comparator arm
Disease control rate at Week 12
NCT01970865 · Phase 1/2
show 5 more results
85.2% (n=27) @ 12wk
Disease control rate at Week 12
NCT01970865 · Phase 1/2
68.3% (n=60) @ 12wk
Disease control rate at Week 12
NCT01970865 · Phase 1/2
64.6% (n=65) @ 12wk
Disease control rate at Week 12
NCT01970865 · Phase 1/2
50% (n=46) @ 12wk
Disease control rate at Week 12
NCT01970865 · Phase 1/2
66% (n=47) @ 12wk
Disease control rate at Week 12
NCT01970865 · Phase 1/2
Disease Control 83.3% (n=30) @ 24wk
responder rate · % of participants
No placebo or comparator arm
Disease control rate at Week 24
NCT01970865 · Phase 1/2
show 5 more results
63% (n=27) @ 24wk
Disease control rate at Week 24
NCT01970865 · Phase 1/2
51.7% (n=60) @ 24wk
Disease control rate at Week 24
NCT01970865 · Phase 1/2
49.2% (n=65) @ 24wk
Disease control rate at Week 24
NCT01970865 · Phase 1/2
32.6% (n=46) @ 24wk
Disease control rate at Week 24
NCT01970865 · Phase 1/2
48.9% (n=47) @ 24wk
Disease control rate at Week 24
NCT01970865 · Phase 1/2

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Foritinib succinate's landscape · Lorlatinib's landscape